Reteplase

證據等級: L5

預測適應症: 10 個

Reteplase: From Acute Myocardial Infarction (STEMI) to Posteroinferior Myocardial Infarction

One-Sentence Summary

Reteplase is a recombinant tissue plasminogen activator (r-tPA variant) used as thrombolytic therapy for acute ST-elevation myocardial infarction (STEMI). The TxGNN model’s top-ranked prediction, Posteroinferior Myocardial Infarction, is flagged by the evidence pack itself as an anatomical subtype of reteplase’s existing MI indication rather than a genuine new indication, and it is supported by 0 clinical trials and 0 publications. A more substantive signal exists further down the candidate list — Septal Myocardial Infarction (rank 5–6) is backed by a completed Phase 3 RCT (n=2,461).

Quick Overview

Item	Content
Original Indication	Acute myocardial infarction (STEMI) — thrombolytic therapy (per repurposing-rationale text in the evidence pack; not confirmed against a Danish SmPC, as the product currently holds no Danish marketing authorisation)
Predicted New Indication	Posteroinferior Myocardial Infarction (anatomical subtype of the existing indication — see caveat below)
TxGNN Prediction Score	99.90%
Evidence Level	L4
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not available for reteplase in this evidence pack [DG002]. Based on known pharmacology, reteplase is a third-generation recombinant plasminogen activator (an engineered tPA variant) that catalyses conversion of plasminogen to plasmin, dissolving fibrin clots in occluded coronary arteries — the basis of its approved use in acute MI/STEMI.

Important caveat on the top-ranked candidate: the evidence pack’s own repurposing rationale states that “posteroinferior myocardial infarction” is not a true new indication. TxGNN’s near-identical scores across ranks 1–4 (posteroinferior MI, posterolateral MI) reflect semantic overlap in the knowledge graph between MI anatomical subtypes and MI generally, not a novel mechanistic link. No independent trials or literature were found for these subtype-labelled terms. This should be treated as an ontology artifact — an extension of the existing indication rather than a repurposing candidate.

A more genuine signal appears at rank 5–6, Septal Myocardial Infarction, supported by a completed Phase 3, multicentre, double-blind, placebo-controlled RCT (NCT00046228, n=2,461) evaluating reteplase plus abciximab in acute MI — directly on-mechanism, and evaluated at decision stage S3 with a “Proceed with Guardrails” recommendation. Ranks 9–10 (coronary stenosis) are similarly supported by several observational/cohort studies (GUSTO-V, SPEED/GUSTO-4 pilot) consistent with reteplase’s core fibrinolytic mechanism, though no trial is registered under that exact disease label.

Clinical Trial Evidence

Currently no related clinical trials registered for Posteroinferior Myocardial Infarction (the ranked #1 candidate).

For reference, the strongest trial evidence in this evidence pack relates to Septal Myocardial Infarction (rank 5–6):

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00046228	Phase 3	Completed	2,461	Multicentre, randomized, double-blind, placebo-controlled trial comparing reteplase + abciximab combination therapy vs. abciximab alone before primary PCI in acute MI.

Literature Evidence

Currently no related literature available for Posteroinferior Myocardial Infarction (the ranked #1 candidate).

Denmark Market Information

Reteplase currently holds 0 marketing authorisations in Denmark (market_status: 未上市 / Not marketed). No Laegemiddelstyrelsen national or EMA centralised licence records are present in this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug-interaction data were not available in this evidence pack [DG001 — Blocking: TFDA/SmPC label text not yet retrieved].

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked candidate (Posteroinferior Myocardial Infarction) is an anatomical subtype of reteplase’s existing approved indication rather than a novel repurposing signal, has zero supporting trials or literature, and is explicitly flagged in the evidence pack as a knowledge-graph ontology artifact. Combined with the blocking gap on Danish label/safety data (DG001) and missing MOA confirmation (DG002), this candidate cannot proceed past initial screening.

To proceed, the following is needed:

Danish SmPC / regulatory label text (warnings, contraindications, DDI) — currently blocking (DG001)
Confirmed mechanism of action data from DrugBank (DG002)
A decision on whether MI anatomical-subtype predictions (ranks 1–4, 7–8) should be excluded from the candidate pipeline as ontology duplicates, or re-scored against the parent “myocardial infarction” indication
If pursuing an evidence-backed candidate instead, Septal Myocardial Infarction (L1 evidence, Phase 3 RCT, “Proceed with Guardrails”) and Coronary Stenosis (L3 evidence, multiple cohort studies) warrant separate evaluation as the more substantive repurposing signals in this evidence pack
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.